Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies
Importance Longitudinal circulating tumor DNA (ctDNA) has been shown to predict response
and survival in patients with metastatic melanoma treated with anti–programmed cell death
1 (PD-1) antibodies. Pseudoprogression, defined as radiologic finding of disease
progression prior to response, has been a challenge to clinicians. Objective To establish
whether ctDNA at baseline and up to week 12 of treatment can differentiate between the
radiologic findings of pseudoprogression and true progression in patients with metastatic …
and survival in patients with metastatic melanoma treated with anti–programmed cell death
1 (PD-1) antibodies. Pseudoprogression, defined as radiologic finding of disease
progression prior to response, has been a challenge to clinicians. Objective To establish
whether ctDNA at baseline and up to week 12 of treatment can differentiate between the
radiologic findings of pseudoprogression and true progression in patients with metastatic …